OPEN END TURBO OPTIONSSCHEIN SHORT - BRISTOL-MYERS SQUIBB | Real-time BOERSE MUENCHEN 13:25:51 27/06/2024 BST | ||
| 0.845 EUR | +0.84% |
|
| Current month | -13.43% | ||
| 1 month | -10.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 0.845 | +0.84% |
| 26/06/24 | 0.838 | -4.99% |
| 25/06/24 | 0.882 | +1.97% |
| 24/06/24 | 0.865 | -7.78% |
| 21/06/24 | 0.938 | -6.39% |
Real-time BOERSE MUENCHEN
Last update June 27, 2024 at 01:25 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | Goldman Sachs |
| WKN | GG623B |
| ISIN | DE000GG623B4 |
| Date issued | 11/04/2024 |
| Strike | 51.57 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.12 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.065 € |
|---|---|
| Lowest since issue | 0.209 € |
| Spread | 0.01 € |
| Spread % | 1.18% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.5
USD
Average target price
53.19
USD
Spread / Average Target
+25.16%
- Stock Market
- Certificates
- Certificat
